NCM and ImaginAb Ink Clinical Isotope Supply and Labeling Agreement
NEW YORK and LOS ANGELES, June 10, 2014 /PRNewswire/ -- NCM USA announced today it has signed a long-term clinical zirconium isotope (89Zr) supply and cGMP biologics labeling agreement with ImaginAb, Inc., an innovation leader in the use of biologics for imaging with Positron Emission Tomography (PET).
The NCM radiopharmaceutical manufacturing footprint specializes in "next generation" cyclotron-generated PET isotopes, including 89Zr, and incorporates advanced automation and multi-product processing capabilities with specialist infrastructure for radiolabeling biologics and macromolecules.
"Our ultra-modern facility in New York has allowed us to attract highly innovative companies such as ImaginAb to develop advanced biologics-based products for PET imaging and we are pleased that ImaginAb selected us as a partner," commented Anwer Rizvi, President of NCM. "Our mission is to elevate the status of centralized PET drug manufacturing to the standard that the biopharma industry has enjoyed for many years."
Christian Behrenbruch, CEO of ImaginAb commented, "NCM is an example of what a technology-enabled PET manufacturing facility can be and where the field ultimately needs to progress in terms of flexibility and multi-isotope production. We have chosen to partner with NCM to bring rapid clinical proof-of-concept development capabilities to both internal pipeline development and potentially some of our third-party pharma collaborations."
About NCM USA, LLC
NCM is a privately-held manufacturer of Positron Emission Tomography (PET) radiopharmaceuticals. NCM is headquartered in in Manhattan NY with a state-of-the-art manufacturing facility in the Bronx. The growing demand for innovative imaging solutions for the management of cancer, neurodegeration and heart disease will require new strategies for isotope production and NCM is poised to deliver.
For more information, visit www.ncm-usa.com
About ImaginAb, Inc.
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging with Positron Emission Tomography (PET). The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare.
For more information, visit www.imaginab.com
SOURCE ImaginAb, Inc.